| 2501 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
47 |
| 2502 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
29 |
| 2503 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
66 |
| 2504 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2505 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
40 |
| 2506 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
56 |
| 2507 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
69 |
| 2508 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
59 |
| 2509 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
56 |
| 2510 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2511 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
66 |
| 2512 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2513 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
64 |
| 2514 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
64 |
| 2515 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2516 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
65 |
| 2517 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2518 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
44 |
| 2519 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
66 |
| 2520 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
48 |
| 2521 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
45 |
| 2522 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
67 |
| 2523 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
69 |
| 2524 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
72 |
| 2525 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
53 |
| 2526 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
71 |
| 2527 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
66 |
| 2528 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
57 |
| 2529 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
74 |
| 2530 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
72 |
| 2531 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome Lb High Risk |
Hematology |
2023 |
Standard Therapy |
Poland |
58 |
| 2532 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome With Multilineage Dysplasia |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2533 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome/Acute Myelogenous Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
42 |
| 2534 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome-Eb1 |
Hematology |
2023 |
Standard Therapy |
Poland |
48 |
| 2535 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
73 |
| 2536 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
76 |
| 2537 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2538 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
5 |
| 2539 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
65 |
| 2540 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
56 |
| 2541 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2542 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
69 |
| 2543 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
61 |
| 2544 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2545 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2546 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2023 |
Standard Therapy |
Poland |
50 |
| 2547 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2023 |
Standard Therapy |
Poland |
54 |
| 2548 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2023 |
Standard Therapy |
Poland |
60 |
| 2549 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2550 |
Apheresis |
Autologous |
No Data |
Hematology |
2023 |
Standard Therapy |
Germany |
69 |
| 2551 |
Apheresis |
Autologous |
No Data |
Hematology |
2023 |
Standard Therapy |
Germany |
53 |
| 2552 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
50 |
| 2553 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
23 |
| 2554 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
39 |
| 2555 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
2 |
| 2556 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
52 |
| 2557 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
61 |
| 2558 |
Apheresis |
Autologous |
No Data |
Hematology |
2023 |
Standard Therapy |
Germany |
60 |
| 2559 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
71 |
| 2560 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
44 |
| 2561 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
72 |
| 2562 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
66 |
| 2563 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
33 |
| 2564 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
42 |
| 2565 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2566 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
19 |
| 2567 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
54 |
| 2568 |
Apheresis |
Autologous |
Nonseminoma, Relapse |
Hematology |
2023 |
Standard Therapy |
Germany |
48 |
| 2569 |
Apheresis |
Allogeneic |
Orofacial Myofunctional Disorders (OMDS), Primary Myelofibrosis (PMF) |
Hematology |
2023 |
Standard Therapy |
Poland |
69 |
| 2570 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
60 |
| 2571 |
Apheresis |
Allogeneic |
Other Immune System |
Hematology |
2023 |
Standard Therapy |
Poland |
71 |
| 2572 |
Apheresis |
Allogeneic |
Other Malignancy |
Hematology |
2023 |
Standard Therapy |
Poland |
49 |
| 2573 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
56 |
| 2574 |
Apheresis |
Allogeneic |
Other Non-Malignant Disease |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2575 |
Apheresis |
Allogeneic |
Paroxysmal Nocturnal Hemoglobinuria (Pnh) |
Hematology |
2023 |
Standard Therapy |
Poland |
36 |
| 2576 |
Apheresis |
Allogeneic |
Peripheral T-Cell Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
47 |
| 2577 |
Apheresis |
Autologous |
Plasma Cell Leukemia |
Hematology |
2023 |
Standard Therapy |
Germany |
70 |
| 2578 |
Apheresis |
Autologous |
Plasma Cell Leukemia |
Hematology |
2023 |
Standard Therapy |
Germany |
56 |
| 2579 |
Apheresis |
Autologous |
Plasmacytoma |
Hematology |
2023 |
Standard Therapy |
Germany |
63 |
| 2580 |
Apheresis |
Allogeneic |
Post Therapeutic Myelodysplastic Syndrome /Acute Myelogenous Leukemia After Chronic Lymphocytic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
60 |
| 2581 |
Apheresis |
Allogeneic |
Post–Polycythemia Vera Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
38 |
| 2582 |
Apheresis |
Allogeneic |
Pra B-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
20 |
| 2583 |
Apheresis |
Allogeneic |
Pre-B-Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
41 |
| 2584 |
Apheresis |
Allogeneic |
Pre-B-Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
61 |
| 2585 |
Apheresis |
Allogeneic |
Pre-B-Acute Myelogenous Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
11 |
| 2586 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2023 |
Standard Therapy |
Germany |
63 |
| 2587 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2023 |
Standard Therapy |
Germany |
73 |
| 2588 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Germany |
70 |
| 2589 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2590 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2591 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
31 |
| 2592 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2593 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Germany |
46 |
| 2594 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2595 |
Apheresis |
Allogeneic |
Relapsed B-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
11 |
| 2596 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
55 |
| 2597 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
58 |
| 2598 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
36 |
| 2599 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
62 |
| 2600 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
9 |